Insider Trading March 16, 2026

RENN Fund Executive Adds to Personal Stake with $3,458 Purchase

President Murray Stahl buys 1,154 shares as RCG trades near its 52-week high

By Leila Farooq RCG
RENN Fund Executive Adds to Personal Stake with $3,458 Purchase
RCG

Murray Stahl, President and Co-Portfolio Manager of RENN Fund, Inc. (RCG), purchased 1,154 shares on March 13, 2026, at $3.05 per share, bringing his direct holdings to 154,934 shares. The trades, executed at a level close to the fund's 52-week high, totaled $3,458. InvestingPro assigns RCG a financial health rating of "GOOD" and notes five additional ProTips for investors.

Key Points

  • Murray Stahl purchased 1,154 shares of RENN Fund, Inc. (RCG) on March 13, 2026, at $3.05 per share, totaling $3,458.
  • Following the purchase, Stahl directly holds 154,934 shares; RCG shares trade near a 52-week high of $3.09 and are up 17.9% year-to-date.
  • InvestingPro rates RCG's financial health as "GOOD" and lists five additional ProTips for investors seeking deeper insight - this is relevant to investors and the asset management sector.

Murray Stahl, who serves as President and Co-Portfolio Manager of RENN Fund, Inc. (RCG), completed a direct purchase of common stock on March 13, 2026. The transaction consisted of 1,154 shares bought at $3.05 per share, resulting in an aggregate outlay of $3,458.

The purchase price of $3.05 per share sits just below the fund's reported 52-week high of $3.09. RCG shares have produced a 17.9% return so far year-to-date.

After this acquisition, Stahl's direct ownership in RENN Fund stands at 154,934 shares. The filings indicate that all of the shares in this particular round of purchases were executed at the identical price of $3.05.

Disclosure within the filings also describes a broader set of interests held indirectly. Those indirect holdings are associated with Stahl's spouse and a collection of entities identified as Fromex Equity Corp., FRMO Corp., Horizon Common Inc., Horizon Kinetics Hard Assets LLC, and Horizon Kinetics Asset Management LLC. Stahl explicitly disclaims beneficial ownership of the shares held by these entities except to the extent of his pecuniary interest.

Market data referenced alongside the filing notes that InvestingPro characterizes RENN Fund's financial health as "GOOD." The same service is cited as offering five additional ProTips intended to give investors further analytical perspective on RCG.

The transaction represents a straightforward insider buy recorded at a single per-share price point and leaves Stahl with a substantial direct holding in the fund. The filings do not provide further commentary on intent beyond the standard ownership disclosures and the identification of the related indirect holders.


Contextual note - The information above is drawn from the reported insider transaction and related disclosures contained in the company's filing. Where the filing lists indirect holders, the reporting individual disclaims beneficial ownership except as described.

Risks

  • The purchase size is modest relative to total holdings - while notable, the small dollar amount may limit the transaction's signal for broader market participants. This impacts investor interpretation within financial markets and asset management.
  • Indirect ownership through multiple entities complicates the ownership picture and may obscure the full extent of influence or economic exposure; this bears on governance and regulatory scrutiny in the financial services sector.
  • The filing does not include commentary on rationale or future intent, leaving uncertainty about whether the purchase reflects a strategic shift or a one-time accumulation; limited disclosure affects investor assessment in capital markets.

More from Insider Trading

Marvell Technology President Sells $1.1M in Stock as Shares Trade Near Yearly High Apr 6, 2026 Edward Lampert Sells $58.5 Million in Lands’ End Stock; Company Posts Q4 Shortfall, Announces $100M Buyback Program Apr 6, 2026 NeonC/NeOnc President Buys $153,398 in Stock as Company Advances Financing and Clinical Timeline Apr 6, 2026 Edwards Lifesciences Executive Executes Option Exercise, Sells 1,019 Shares Apr 6, 2026 Penumbra Director Executes $32,822 Stock Sale Amid Deal and Upbeat Quarterly Results Apr 6, 2026